Diligence memo · auto-generated · as of July 2, 2026

Codetta Bio Inc.

Codetta Bio Inc. looks over-valued against its niche peers and is quiet on financing cadence.

SourceRaising on rhythm with a 5.4× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Codetta Bio Inc. operates in Biotechnology, based in MORRISVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Codetta Bio Inc. has raised $12M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $12M on 2024-05-21.

Most recent recorded round closed around 2024-05-21.

Valuation (modeled)modeled

Provath models Codetta Bio Inc. at approximately $68M (range $13M–$151M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.54× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 2.1 yr ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

Comparablesmixed

Capital scale ranks ahead of 60% of Biotechnology peers (4291 compared).

Modeled value ranks above 52% of those peers.

Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.